Rare disease focus Quoin specializes in rare and orphan diseases, presenting a clear sales opportunity to niche specialty channels, patient advocacy groups, and specialty pharmacies that cater to Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa.

US and Europe Ready With plans to establish a sales infrastructure in the U.S. and Europe and to pursue strategic licensing for other territories, there are potential parallel paths for direct commercial launch and regional partnerships to accelerate market access.

Clinical momentum Active development of lead assets and novel formulations (rapamycin via Invisicare technology) suggests opportunities to engage in partner-sourced trials, investigator-initiated studies, and co-development discussions with contract research organizations and academic centers.

Strategic partnerships Recent activity includes partnerships with Maxim Group for financing and a research agreement with University College Cork, signaling openness to investment, licensing, and research collaborations that can extend pipeline reach and clinical data generation.

Branding and awareness Launch of patient-focused initiatives such as the NETHERTON NOW video series indicates a channel to build patient engagement and advocacy partnerships, which can drive demand generation and support for payer discussions in rare disease segments.